- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
PMCPA ruled Lilly’s open-access “patient” section listed diabetes brands/logos with promotional language and no general-public section, amounting to promotion of POMs to…
Former employee alleged inducements to switch to branded products, disguised NHS meetings and over-promotion of Zineryt 90ml. Panel found complainant provided little…
A consultant challenged an Asacol leavepiece claiming “up to 72% treatment success”. Panel found it misleading, but the Appeal Board ruled the…
A GP alleged Novo Nordisk promoted Victoza (liraglutide) for weight loss via Daily Mail coverage. The Panel had concerns about media engagement…
PMCPA case summary: Director v Merck Sharp & Dohme (AUTH/3086/9/18). Case text not provided in CASE_TEXT, so details of allegations, outcome, clauses…
An Allergan employee used a personal Twitter account to message a contact linked to a patient organisation, naming Botox and suggesting work…
BMJ trial-tracker data suggested 1 Bayer “due” EUCTR trial lacked results (98.6% reported). Bayer showed the trial was withdrawn before recruitment, so…
PMCPA case AUTH/3095/9/18 (Director v Actelion) concerned clinical trial disclosure. Under the 2016 ABPI Code it was ruled outwith the scope of…
PMCPA case AUTH/3074/9/18 (Director v AbbVie) concerned clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…
Efient leavepiece used prominent 15‑month subgroup/landmark data and downplayed overall bleeding risk. PMCPA ruled it misleading, inconsistent with SPC (12‑month recommendation), and…
A GP complained about faxed advisory board invitations addressed to “All GPs” and an unnamed recipient, plus inconsistent fees. PMCPA found a…
Novo Nordisk co-sponsored an evening restaurant meeting in Dec 2011 that invitees saw as a Christmas meal. PMCPA found breaches of Clauses…
Anonymous clinician alleged a Lilly/Boehringer Ingelheim diabetes meeting was a sales event disguised as education. Panel found the meeting had clear educational…
A health professional complained that a symposium invite referencing “new data from clinical trials” implied promotion of unpublished/unlicensed information. The Panel found…
Baxter UK was ruled in breach of Clause 9.1 after exhibiting at a Northern Ireland urology meeting held at a 5-star venue…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.